8.40
price down icon5.41%   -0.48
after-market Handel nachbörslich: 8.40
loading
Schlusskurs vom Vortag:
$8.88
Offen:
$8.72
24-Stunden-Volumen:
161.06K
Relative Volume:
1.19
Marktkapitalisierung:
$722.69M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
89.84
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
+8.81%
1M Leistung:
-13.49%
6M Leistung:
-40.64%
1J Leistung:
-45.84%
1-Tages-Spanne:
Value
$8.26
$9.385
1-Wochen-Bereich:
Value
$7.67
$9.385
52-Wochen-Spanne:
Value
$6.11
$19.00

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name
Firmenname
Gyre Therapeutics Inc
Name
Telefon
(619) 949-3681
Name
Adresse
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Name
Mitarbeiter
574
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
GYRE's Discussions on Twitter

Vergleichen Sie GYRE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GYRE
Gyre Therapeutics Inc
8.40 722.69M 106.66M 15.16M 6.37M 0.0935
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-11 Eingeleitet Noble Capital Markets Outperform
2021-04-29 Fortgesetzt Stephens Overweight
2021-02-10 Eingeleitet Piper Sandler Overweight
2020-05-21 Eingeleitet Raymond James Outperform
2019-01-04 Eingeleitet Oppenheimer Outperform
2018-02-12 Bestätigt B. Riley FBR, Inc. Buy
2018-02-09 Bestätigt Chardan Capital Markets Buy
2017-12-08 Eingeleitet B. Riley FBR, Inc. Buy
2017-06-12 Eingeleitet Chardan Capital Markets Buy
2017-06-06 Eingeleitet Ladenburg Thalmann Buy
2016-06-30 Eingeleitet Rodman & Renshaw Buy
Alle ansehen

Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten

pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Apr 14, 2025
pulisher
Apr 09, 2025

GYRE Stock Plummets to 52-Week Low at $6.15 Amid Market Challenges - Investing.com Canada

Apr 09, 2025
pulisher
Mar 31, 2025

GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges - Investing.com UK

Mar 31, 2025
pulisher
Mar 31, 2025

Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Major Breakthrough: Gyre's Cancer Drug Trial Targets 25% of Radiation Therapy Patients - Stock Titan

Mar 31, 2025
pulisher
Mar 30, 2025

Bank of New York Mellon Corp Has $168,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Mar 30, 2025
pulisher
Mar 27, 2025

Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - Stock Titan

Mar 27, 2025
pulisher
Mar 25, 2025

Gyre therapeutics president Ma Songjiang sells common stock for $1,740 By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Gyre therapeutics president Ma Songjiang sells common stock for $1,740 - Investing.com Australia

Mar 25, 2025
pulisher
Mar 23, 2025

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Gyre therapeutics president Ma Songjiang sells $40,440 in stock By Investing.com - Investing.com Canada

Mar 22, 2025
pulisher
Mar 21, 2025

Gyre therapeutics president Ma Songjiang sells $40,440 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Gyre Therapeutics president Ma Songjiang sells $26,658 in stock By Investing.com - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

Gyre Therapeutics president Ma Songjiang sells $26,658 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Gyre Therapeutics Inc (GYRE) Q4 2024 Earnings: Revenue Surpasses Estimates at $27.9M, EPS Misses at $0.00 - GuruFocus.com

Mar 19, 2025
pulisher
Mar 19, 2025

Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 18, 2025

Decoding Gyre Therapeutics Inc (GYRE): A Strategic SWOT Insight - GuruFocus

Mar 18, 2025
pulisher
Mar 17, 2025

Gyre Therapeutics offers weak 2025 revenue guidance - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases -March 17, 2025 at 04:52 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

(GYRE) Gyre Therapeutics Sees 2025 Revenue Range $118M$128M -March 17, 2025 at 04:18 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 14, 2025

FY2024 Earnings Forecast for GYRE Issued By Noble Financial - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Gyre Therapeutics president Ma Songjiang sells $46,280 in stock By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 13, 2025

Gyre Therapeutics president Ma Songjiang sells $46,280 in stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 13, 2025
pulisher
Mar 12, 2025

Exploring High Growth Tech Stocks In The US March 2025 - Simply Wall St

Mar 12, 2025
pulisher
Mar 12, 2025

Gyre therapeutics president Ma Songjiang sells $40,776 in stock By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Gyre therapeutics president Ma Songjiang sells $40,776 in stock - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Gyre Therapeutics initiated with an Outperform at Noble Capital - TipRanks

Mar 11, 2025
pulisher
Mar 09, 2025

Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Still a Buy? - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Gyre Therapeutics president Ma Songjiang sells $43,560 in stock - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Gyre Therapeutics president Ma Songjiang sells $43,560 in stock By Investing.com - Investing.com South Africa

Mar 07, 2025

Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):